BackgroundAdolescent depression and anxiety are major public health concerns. Aggression is frequently associated with internalizing symptoms, but the behavioral and body related mechanisms underlying this association remain insufficiently clarified. This study examined a theoretically proposed chain mediation model linking aggression with depressive and anxiety symptoms through internet addiction and somatization.MethodsA cross-sectional survey was conducted among 5,307 high school students in Chongqing, China. Participants filled in the Buss and Perry Aggression Questionnaire (BPAQ), Internet Addiction Test (IAT), Patient Health Questionnaire – 15 (PHQ – 15), Patient Health Questionnaire – 9 (PHQ – 9) and Generalized Anxiety Disorder Scale – 7 (GAD – 7). Regression based chain mediation analyses with 5,000 bootstrap samples were performed using PROCESS Model 6, with gender and age controlled as covariates.ResultsThe results showed that aggression was positively correlated with depressive symptoms (β = 0.256, p < 0.001) and anxiety symptoms (β = 0.275, p < 0.001). Chain mediation analysis showed that aggression was indirectly associated with mental health through three distinct pathways: 1. the independent mediating effect of internet addiction; 2. the independent mediating effect of somatization; 3. the sequential chain mediating effect from internet addiction to somatization. The model explained more variance in depressive symptoms (R² = 58.2%) than in anxiety symptoms (R² = 53.5%). Furthermore, the association between somatization and depressive symptoms (β = 0.457) was stronger than that between somatization and anxiety symptoms (β = 0.428).ConclusionThis study supports a statistically significant chain mediation pattern in which aggression is associated with depressive and anxiety symptoms through internet addiction and somatization. The findings suggest that somatization may represent an important body related correlate in the association between maladaptive digital behavior and emotional distress, with a slightly stronger association observed for depressive symptoms than for anxiety symptoms. These findings highlight the importance of integrated school based interventions that address digital behavior regulation, somatic symptom monitoring, and emotional distress among adolescents with higher aggressive tendencies.
A bibliometric analysis of neuroimaging studies on cognitive control in autism spectrum disorder (2000–2025)
ObjectiveThis study aims to systematically analyze neuroimaging research on cognitive control in Autism spectrum disorder (ASD) from 2000 to 2025 using bibliometric methods, in order to reveal the evolutionary trajectory, core knowledge base, research hotspots, and future frontiers of the field.MethodsA search was conducted on the Web of Science Core Collection and Scopus databases, resulting in the inclusion of 1,581 relevant articles. VOSviewer and the Bibliometrix package in R were utilized to conduct a comprehensive visualization and quantitative analysis of annual publication volume, country/institution/author collaboration networks, keyword co-occurrence, document co-citation, and thematic evolution.Results(1) The volume of research literature showed exponential growth, with an annual growth rate of 21.61%, entering a period of rapid development particularly after 2012, which is closely related to the popularization of functional magnetic resonance imaging (fMRI) technology. (2) “Functional connectivity,” “executive function,” and “default mode network” were the most central keywords. “Functional connectivity” rapidly became a hub connecting various themes after 2010, marking a paradigm shift from “functional localization” to “brain network dysregulation.” (3) The “Triple network model” proposed by Menon was the most cited document, laying the core theoretical foundation for understanding ASD as a disorder of large-scale brain network dysfunction. (4) “Transdiagnostic” research has emerged as a new hotspot, while “multimodal imaging,” “machine learning,” and “dynamic connectivity” represent highly promising future directions.ConclusionOver the past two decades, neuroimaging research on cognitive control in ASD has undergone a profound paradigm shift: from focusing on abnormal activation in isolated brain regions to exploring the static and dynamic dysregulation of large-scale brain networks. The research perspective has also expanded from a single-disorder model to a transdiagnostic framework that includes comparisons with other neurodevelopmental disorders (e.g., ADHD). Future research should focus on the fusion of multimodal data, the application of computational psychiatry methods, and the translation of basic research findings into personalized clinical interventions.
Author Correction: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03180-7
Author Correction: DNA-guided CRISPR–Cas12a effectors for programmable RNA recognition and cleavage
Improving multimodal wearable sensing for healthcare with artificial intelligence
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03134-z
This Comment explores artificial intelligence-driven strategies to accelerate the clinical translation of multimodal wearable sensors. We outline key data-science challenges and highlight disease contexts in which these systems could support therapeutic interventions.
Programming biology: next-gen AI firms raise billions to design better medicines
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03170-9
Faster drug discovery, optimized drug design, even programmable therapeutics: AI is impacting R&D. Data and development bottlenecks remain.
A framework for building a synthetic cell from the SynCell Asia Initiative
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03153-w
Building a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelligence (AI)-driven biofoundry.
Fetal monitoring for high-risk pregnancies using a wearable ultrasound patch
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03140-1
A wearable ultrasound device is optimized for continuous monitoring of pregnancies.
Enabling secure discovery in trusted research environments with improved tooling
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04401-x
Biobanks are introducing trusted research environments to enable secure data access, yet they can increase costs and complexity for biomedical researchers who use them. We discuss challenges and solutions and introduce the Python Phenofhy community tool for Our Future Health.
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
Nature Medicine, Published online: 26 May 2026; doi:10.1038/s41591-026-04376-9
In a multicenter phase 2 trial, the fibroblast growth factor receptor inhibitor rogaratinib showed encouraging clinical efficacy in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumors, suggesting a potential new treatment option for this patient population and demonstrating that an epigenetic mechanism of oncogene activation can be successfully targeted with a tyrosine kinase inhibitor.
Microglial mitochondria transfer to astrocytes via GPNMB-enriched extracellular vesicles alleviates cognitive deficits in tauopathy mice
Nature Neuroscience, Published online: 26 May 2026; doi:10.1038/s41593-026-02317-w
In PS19 mice, microglia-derived glycoprotein nonmetastatic melanoma protein B promotes mitochondrial extracellular vesicle secretion, enabling mitochondrial transfer to astrocytes. This improves astrocytic function and reduces Alzheimer’s disease (AD) symptoms, while GPNMB deficiency impairs it, highlighting new AD treatment avenues.